🇺🇸 FDA

Company profile · Sponsor

LIGAND

LIGAND PHARMACEUTICALS INC

LGND · NYSE pharma SAN DIEGO, CA, USA
Pipeline
24
Drugs
0
Patents
8

Quick answer

LIGAND (LGND) is a pharma company. headquartered in SAN DIEGO, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker LGND
Exchange NYSE
Company type pharma
Headquarters SAN DIEGO, CA, USA
SEC CIK 0000886163

Pipeline (24)

Search pipeline →

  1. Intravenous Carbamazepine (IV CBZ)

    LIGAND

    Epilepsy

    phase 3 small molecule completed

    1 trial

  2. Targretin Gel 1%

    LIGAND

    Alopecia Areata

    phase 3 small molecule completed

    1 trial

  3. lasofoxifene

    LIGAND

    Osteoporosis

    phase 3 small molecule completed

    3 trials

  4. Alitretinoin

    LIGAND

    Sarcoma, Kaposi

    phase 2 small molecule completed

    2 trials

  5. Aplindore

    LIGAND

    Restless Legs Syndrome

    phase 2 small molecule completed

    1 trial

  6. Aplindore

    LIGAND

    Early Stage Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  7. Bexarotene

    LIGAND

    Lung Cancer

    phase 2 small molecule completed

    1 trial

  8. Bexarotene

    LIGAND

    Sarcoma, Kaposi

    phase 2 small molecule completed

    1 trial

  9. Bexarotene (targretin)

    LIGAND

    Carcinoma, Non-small-cell Lung

    phase 2 small molecule terminated

    1 trial

  10. Bexarotene 1% gel

    LIGAND

    Parapsoriasis

    phase 2 small molecule terminated

    1 trial

  11. Bexarotene/NBUVB vs placebo NBUVB

    LIGAND

    Psoriasis

    phase 2 small molecule completed

    1 trial

  12. Budesonide

    LIGAND

    Seasonal Allergic Rhinitis

    phase 2 small molecule completed

    1 trial

  13. Budesonide + Azelastine

    LIGAND

    Seasonal Allergic Rhinitis

    phase 2 small molecule completed

    1 trial

  14. CE-Iohexol

    LIGAND

    Contrast-induced Nephropathy

    phase 2 small molecule terminated

    1 trial

  15. LGD-6972-5 mg

    LIGAND

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  16. Lasofoxifene

    LIGAND

    Bone Loss

    phase 2 small molecule completed

    1 trial

  17. MB07133 300mg/m2/day

    LIGAND

    Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial

  18. MB07803

    LIGAND

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  19. MB07811

    LIGAND

    Hypercholesterolemia

    phase 2 small molecule terminated

    1 trial

  20. PS433540

    LIGAND

    Hypertension

    phase 2 small molecule completed

    1 trial

  21. bexarotene

    LIGAND

    Cutaneous T-Cell Lymphoma

    phase 2 small molecule completed

    1 trial

  22. bexarotene

    LIGAND

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  23. denileukin diftitox

    LIGAND

    Drug/Agent Toxicity by Tissue/Organ

    phase 2 mab completed

    1 trial

  24. erlotinib and bexarotene

    LIGAND

    Carcinoma, Non-small-cell Lung

    phase 2 small molecule completed

    1 trial

Patents (8)

Search patents →

  1. US 12403087

    Topical antiviral compositions, delivery systems, and methods of using the same

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12319651

    Crystalline forms and methods of producing crystalline forms of a compound

    Expires Mon May 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12246014

    Azetidine derivatives

    Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12208071

    Glucagon receptor antagonists

    Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12123012

    Methods and compositions for nucleic acid and protein payload delivery

    Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11970482

    Acetal compounds and therapeutic uses thereof

    Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11952364

    TRK inhibitors useful as anticancer drugs

    Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11773110

    Heterocycle amines and uses thereof

    Expires Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is LIGAND?

LIGAND (LGND) is a pharma company. headquartered in SAN DIEGO, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does LIGAND sponsor?

We track 24 ClinicalTrials.gov-linked programs for LIGAND, including Intravenous Carbamazepine (IV CBZ) and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does LIGAND company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.